Although the methodologies for measuring gene mutation rates differ between BCR::ABL1 and JAK2 V617 F, this suggests that nearly all peripheral blood cells might have carried both BCR::ABL1 and JAK2 V617 F at the onset of CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.